Could a smaller dose of this cancer drug work just as well? a new trial aims to find out.
NCT ID NCT07576725
First seen May 14, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This study is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control advanced cancers that have spread or cannot be removed by surgery. The goal is to see if this cheaper, simpler approach works as well as the standard dose, which could make treatment more accessible worldwide. About 50 adults with various cancers, including melanoma, lung cancer, and kidney cancer, will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Uganda Cancer Institute
Kampala, 3935, Uganda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.